A phase I study of estramustine, weekly docetaxel and carboplatin (EDC) chemotherapy in patients with hormone refractory prostate cancer (HRPC)

William Oh,E. Hagmann,Judith Manola,Daniel J. George,Timothy D. Gilligan,M. R. Smith,Donald S. Kaufman,Philip W. Kantoff

A phase I study of estramustine, weekly docetaxel and carboplatin (EDC) chemotherapy in patients with hormone refractory prostate cancer (HRPC)

2004

William Oh
E. Hagmann
Judith Manola
Daniel J. George
Timothy D. Gilligan
M. R. Smith
Donald S. Kaufman
Philip W. Kantoff

4656 Background: The purpose of this study was to define the maximal tolerated dose (MTD) of weekly docetaxel combined with carboplatin and estramustine in the treatment of patients with HRPC. Meth...

Keywords:

Carboplatin
Chemotherapy
Estramustine
Oncology
Hormone refractory prostate cancer
Internal medicine
Medicine
Docetaxel
in patient
phase i study
Meth-

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations